Literature DB >> 16419490

Ovarian steroids modulate neuroendocrine dysfunction in polycystic ovary syndrome.

S A R Doi1, M Al-Zaid, P A Towers, C J Scott, K A S Al-Shoumer.   

Abstract

OBJECTIVE: Neuroendocrine dysfunction in polycystic ovary syndrome (PCOS) was addressed by studying the steroid hormone changes in women with PCOS with either high or normal LH levels leading to inferences regarding the primacy of elevated LH in the pathophysiology of PCOS.
METHODS: A cross-sectional study was designed in an academic clinical facility involving 234 women with PCOS. Patients were divided into two groups based on an LH/FSH ratio < or >1 and hormonal and metabolic studies were performed in both groups. Factors were determined by binomial logistic regression that predicted group membership of these women.
RESULTS: Higher follicular phase estradiol (E2) and androstenedione (A4) levels as well as greater insulin sensitivity were the only factors that predicted the presence of neuroendocrine dysfunction with elevated A4 being necessary for neuroendocrine dysfunction.
CONCLUSIONS: It was concluded that uncoupling of hypothalamic E2 inhibition by elevated ovarian A4 associated with E2 related sensitization of pituitary LH leads to neuroendocrine dysfunction in PCOS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16419490     DOI: 10.1007/bf03345319

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  72 in total

1.  Variation of luteinizing hormone and androgens in oligomenorrhoea and its implications for the study of polycystic ovary syndrome.

Authors:  M H van Hooff; M van der Meer; C B Lambalk; J Schoemaker
Journal:  Hum Reprod       Date:  1999-07       Impact factor: 6.918

2.  Mild adrenal and ovarian steroidogenic abnormalities in hirsute women without hyperandrogenemia: does idiopathic hirsutism exist?

Authors:  H F Escobar-Morreale; J Serrano-Gotarredona; R García-Robles; J Sancho; C Varela
Journal:  Metabolism       Date:  1997-08       Impact factor: 8.694

3.  Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.

Authors:  L Ibañez; J E Hall; N Potau; A Carrascosa; N Prat; A E Taylor
Journal:  J Clin Endocrinol Metab       Date:  1996-11       Impact factor: 5.958

4.  Insulin resistance in nonobese patients with polycystic ovary syndrome.

Authors:  S Toprak; A Yönem; B Cakir; S Güler; O Azal ; M Ozata; A Corakçi
Journal:  Horm Res       Date:  2001

5.  Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.

Authors:  Miriam E Silfen; Michelle R Denburg; Alexandra M Manibo; Rogerio A Lobo; Richard Jaffe; Michel Ferin; Lenore S Levine; Sharon E Oberfield
Journal:  J Clin Endocrinol Metab       Date:  2003-10       Impact factor: 5.958

Review 6.  Should patients with polycystic ovarian syndrome be treated with metformin?

Authors:  Emre Seli; Antoni J Duleba
Journal:  Hum Reprod       Date:  2002-09       Impact factor: 6.918

7.  Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.

Authors:  R S Legro; D Driscoll; J F Strauss; J Fox; A Dunaif
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

8.  Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion.

Authors:  Ketan Patel; Mickey S Coffler; Michael H Dahan; Richard Y Yoo; Mark A Lawson; Pamela J Malcom; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

9.  Endocrine changes after laparoscopic ovarian cautery in polycystic ovarian syndrome.

Authors:  E Greenblatt; R F Casper
Journal:  Am J Obstet Gynecol       Date:  1987-02       Impact factor: 8.661

10.  The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women.

Authors:  J Holte; T Bergh; G Gennarelli; L Wide
Journal:  Clin Endocrinol (Oxf)       Date:  1994-10       Impact factor: 3.478

View more
  6 in total

1.  A case of major depressive disorder and symptoms of polycystic ovary syndrome responding to escitalopram.

Authors:  Sergio L Blay
Journal:  Prim Care Companion CNS Disord       Date:  2011

Review 2.  Neuroendocrine dysfunction in PCOS: a critique of recent reviews.

Authors:  Suhail A R Doi
Journal:  Clin Med Res       Date:  2008-09

3.  The Association of CYP17A1, CYP19A1, and SHBG Gene Polymorphisms in Polycystic Ovary Syndrome Susceptibility: A Systematic Review and Meta-Analysis.

Authors:  Chuan Xing; Han Zhao; Jiaqi Zhang; Bing He
Journal:  Front Physiol       Date:  2022-05-09       Impact factor: 4.755

Review 4.  Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan.

Authors:  H Teede; A Deeks; L Moran
Journal:  BMC Med       Date:  2010-06-30       Impact factor: 8.775

5.  Polycystic ovary syndrome - A metabolic malady, the mother of all lifestyle disorders in women - Can Indian health budget tackle it in future?

Authors:  M Ashraf Ganie; Sanjay Kalra
Journal:  Indian J Endocrinol Metab       Date:  2011-10

6.  Understanding polycystic ovary syndrome from the patient perspective: a concept elicitation patient interview study.

Authors:  Mona L Martin; Katarina Halling; Daniel Eek; Meaghan Krohe; Jean Paty
Journal:  Health Qual Life Outcomes       Date:  2017-08-18       Impact factor: 3.186

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.